Results 91 to 100 of about 2,421 (106)

A Clinicopathological Description of Kidney Features in VEXAS Syndrome. [PDF]

Kidney Int Rep
Mathurin M, Hirsch P, Jachiet V, Hadjadj J, Le Guenno G, Heiblig M, Pelletier S, Mathian A, Garrouste C, Lavergne A, Ardois S, Flejeo J, Masson I, Boukerroucha Z, Perrin F, Magnol M, Constantin A, Dion J, Comont T, Huart A, Kemeny JL, Picard C, Colombat M, Le Naoures C, Benard L, Sannier A, Vrtovsnik F, Brocheriou I, Pastoret C, Sujobert P, Delabesse E, Kosmider O, Delhommeau F, Mekinian A, Georgin-Lavialle S, Buob D, El Karoui K, FRENVEX Group.   +37 more
europepmc   +1 more source

18F-FDG brain/cerebellum-to-liver ratios as prognostic factors. [PDF]

Blood Cancer J
Morland D, Durot E.
europepmc   +1 more source

Encéphalopathie hyperammoniémique après une chimiothérapie par 5-fluorouracile. [PDF]

CMAJ
Salimi P, Soriano A, Crocker E, Goldenberg B.   +3 more
europepmc   +1 more source

Correction: Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium. [PDF]

Bone Marrow Transplant
Marton C, Clémenceau B, Dachy G, Demerle C, Derenne S, Ferrand C, Giverne C, Latouche JB, Lemée L, Martinet J, Bonig H, Bensoussan D, Chabannon C, Köhl U, Deschamps M, De Vos J, Diana JS, Dougé A, Forcade E, Galaine J, Thiant S, Galy A, Larghero J, Reppel L, Viel S, Boyer O, Yakoub-Agha I.   +26 more
europepmc   +1 more source

The EMMY longitudinal, cohort study: real-world data to describe multiple myeloma management and outcomes as more therapeutic options emerge. [PDF]

Clin Hematol Int
Decaux O, Garlantézec R, Belhadj-Merzoug K, Macro M, Frenzel L, Perrot A, Moreau P, Royer B, Caillot D, Leleu X, Mohty M, Karlin L, Feugier P, Rigaudeau S, Fontan J, Sonntag C, Vincent L, Chalopin T, Avet Loiseau H, Maarouf Z, Chanaz L, Texier N, Hulin C.   +22 more
europepmc   +1 more source

Olutasidenib as maintenance therapy after treatment response in acute myeloid leukemia with persistent <i>IDH1</i> mutation. [PDF]

Blood Neoplasia
Jonas BA, Seiter K, Wei AH, Wang ES, Wang S, Sheppard AD, de Botton S.   +6 more
europepmc   +1 more source

Evaluating a predictive model of tyrosine kinase inhibitor therapy failure in a European-type cohort: a step towards population-specific tools. [PDF]

Leukemia
Moinard S, Lebecque B, Lachaise T, Johnson-Ansah H, Doublet C, Roth-Guepin G, Rigal-Huguet F, Roy L, Parry A, Meunier M, Penot A, Legros L, Pante V, Escoffre-Barbe M, Rousselot P, Denis G, Monjanel H, Hamroun D, Khlaifia A, Besombes J, Pereira B, Bourgne C, Berger MG.   +22 more
europepmc   +1 more source

PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome. [PDF]

J Clin Med
Beck DB, Heiblig M, Savic S, Ferrada MA, Mekinian A, Chowdhury O, Hammond D, Weeks LD, Gurnari C, Kirino Y, Georgin-Lavialle S, Buckley SA, Garcha R, Harder BG, Koster MJ.   +14 more
europepmc   +1 more source

Ultra-high-sensitivity next-generation sequencing-based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort. [PDF]

Blood Cancer J
Boudry A, Fenwarth L, Itzykson R, Braun T, Adès L, Fournier É, Berthon C, Lebon D, De Botton S, Peffault de Latour R, Pautas C, Dombret H, Raffoux E, Gardin C, Celli-Lebras K, Preudhomme C, Duployez N.   +16 more
europepmc   +1 more source

Ruxolitinib and Hydroxycarbamide Are the Most Efficient Drugs to Reduce Aquagenic Pruritus Intensity in a Real-Word Cohort of Patients With Myeloproliferative Neoplasms. [PDF]

EJHaem
Gall-Ianotto CL, Civi L, Pan-Petesch B, Herbreteau L, Rio L, Lambert WC, Misery L, Lippert E, Ianotto JC.   +8 more
europepmc   +1 more source